Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7ZYM

Crystal Structure of EGFR-T790M/C797S in Complex with Brigatinib

7ZYM の概要
エントリーDOI10.2210/pdb7zym/pdb
分子名称Epidermal growth factor receptor, 5-chloro-N~4~-[2-(dimethylphosphoryl)phenyl]-N~2~-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine (3 entities in total)
機能のキーワードegfr, t790m/c797s, inhibitor, transferase
由来する生物種Homo sapiens (human)
タンパク質・核酸の鎖数1
化学式量合計38299.70
構造登録者
Niggenaber, J.,Kleinboelting, S.,Mueller, M.P.,Rauh, D. (登録日: 2022-05-25, 公開日: 2023-05-03, 最終更新日: 2024-02-07)
主引用文献Grabe, T.,Jeyakumar, K.,Niggenaber, J.,Schulz, T.,Koska, S.,Kleinbolting, S.,Beck, M.E.,Muller, M.P.,Rauh, D.
Addressing the Osimertinib Resistance Mutation EGFR-L858R/C797S with Reversible Aminopyrimidines.
Acs Med.Chem.Lett., 14:591-598, 2023
Cited by
PubMed Abstract: Drug resistance mutations emerging during the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) inhibitors represent a major challenge in personalized cancer treatment and require constant development of new inhibitors. For the covalent irreversible EGFR inhibitor osimertinib, the predominant resistance mechanism is the acquired C797S mutation, which abolishes the covalent anchor point and thus results in a dramatic loss in potency. In this study, we present next-generation reversible EGFR inhibitors with the potential to overcome this EGFR-C797S resistance mutation. For this, we combined the reversible methylindole-aminopyrimidine scaffold known from osimertinib with the affinity driving isopropyl ester of mobocertinib. By occupying the hydrophobic back pocket, we were able to generate reversible inhibitors with subnanomolar activity against EGFR-L858R/C797S and EGFR-L858R/T790M/C797S with cellular activity on EGFR-L858R/C797S dependent Ba/F3 cells. Additionally, we were able to resolve cocrystal structures of these reversible aminopyrimidines, which will guide further inhibitor design toward C797S-mutated EGFR.
PubMed: 37197473
DOI: 10.1021/acsmedchemlett.2c00514
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.5 Å)
構造検証レポート
Validation report summary of 7zym
検証レポート(詳細版)ダウンロードをダウンロード

236371

件を2025-05-21に公開中

PDB statisticsPDBj update infoContact PDBjnumon